Educational reference only. Not medical advice. Consult a healthcare provider before starting any protocol.
BPC-157
Body Protection Compound-157
What it is
BPC-157 is a synthetic peptide consisting of 15 amino acids, derived from a partial sequence of a protein found in human gastric juice. It has been studied in animal models in the context of tissue repair, tendon and ligament healing, and gastrointestinal protection. Preclinical research has explored its potential interactions with nitric oxide and growth factor pathways. It is frequently discussed in biohacking and longevity communities.
Community-reported ranges
Ranges sourced from community forums and published preclinical literature. Not dosing guidance.
Reported dose range
200–500 mcg
Estimated half-life
~4 hours
Source: Preclinical data
Reported cycle length
4–8 weeks on
2–4 weeks off
Route
Subcutaneous
Common vial sizes
5mg, 10mg
Reported timing
AM & PM
Reported frequency
1–2x daily
Frequently discussed alongside
Based on community forum discussions. Not a recommendation to combine compounds.
Published research
BPC-157 has been the subject of extensive preclinical research, primarily in rodent models. Published studies have investigated its effects on tendon-to-bone healing, muscle injury recovery, gastrointestinal mucosal integrity, and vascular function. Several papers describe interactions with the nitric oxide system and various growth factor pathways. As of the current date, no completed human clinical trials have been published in peer-reviewed journals. All dosing information available in community forums is extrapolated from animal study data.
Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.
Current Pharmaceutical Design
Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.
Journal of Applied Physiology
Seiwerth S, et al. BPC 157's effect on healing.
Journal of Physiology – Paris
Reported side effects
From community self-reports. Not from controlled studies.
Community self-reports include: nausea, dizziness, and mild headache. Some users report feeling lightheaded after administration. These are anecdotal reports from community forums, not findings from controlled clinical studies.
Regulatory status
FDA (United States)
Not approved. Category 2 — prohibited for pharmacy compounding.
Health Canada
Not authorized as a therapeutic product. No DIN assigned.
WADA (Competitive Athletes)
Prohibited substance for competitive athletes.